The U.S. Food and Drug Administration's (FDA) chief says the agency will begin offering bonuses to drug reviewers who ...
The plan raises a number of questions, including how the payments will be distributed across large teams of staffers.
Where FDA breakthrough devices stand through 2025: growth, authorizations, leading specialties, AI trends, and qualification pathways explained.
Psychedelic drug development can still benefit from the FDA Commissioner’s National Priority Review Voucher Pilot Program, though the CNPV designation was not given to Compass Pathways’ synthetic ...
The effort by FDA Commissioner Marty Makary, MD, MPH, to drastically shorten the review of drugs favored by President Donald Trump's administration is causing alarm across the agency, stoking worries ...
On October 3, 2025, the U.S. Food and Drug Administration (FDA) unveiled a pilot prioritization program that provides for accelerated review of abbreviated new drug applications (ANDAs) for generic ...
WASHINGTON (AP) — A Democratic lawmaker raised new concerns about a Food and Drug Administration program designed to drastically shorten the review of certain drugs, including whether senior officials ...
On February 24, 2026, the U.S. Food and Drug Administration announced the establishment of new Produce Regulatory Program Standards (PRPS), developed in collaboration with the Nat ...
Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration's headquarters is in Silver Spring, Maryland. The Food and Drug Administration has created a ...
On Feb. 1, 2026, the FDA officially launched its Manufacturing PreCheck Pilot Program, which is intended to de-risk and accelerate the establishment of U.S. pharmaceutical manufacturing facilities by ...
Hosted on MSN
Legal questions swirl around FDA's new expedited drug program, including who should sign off
WASHINGTON (AP) — The Food and Drug Administration commissioner's effort to drastically shorten the review of drugs favored by President Donald Trump's administration is causing alarm across the ...
WASHINGTON (AP) — The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored by President Donald Trump’s administration is causing alarm across the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results